Skip Navigation

Find a Doctor

Find a Researcher

John Joseph Laterra, M.D., Ph.D.

John Joseph Laterra, M.D., Ph.D.

Headshot of John Joseph Laterra
4.9out of 5
52 Ratings
| 18 Comments
  • Co-Director, Brain Cancer Disease Group, Sidney Kimmel Comprehensive Cancer Center
  • Professor of Neurology
Male

Expertise

Brain Tumors, Neurology, Von Hippel-Lindau (VHL)

Research Interests

Mechanisms of Brain Cancer Stem Cell Regulation

Play Video:

Brain Tumor Treatment Advances Over 10 Years: Carlos' Story

Request an Appointment

Insurance Information

Existing Patients

Request your next appointment through MyChart

Main Phone

410-614-3853

Outside of Maryland & Washington D.C.

410-464-6641
Request Appointment

International Patients

+1-410-502-7683
Request Appointment

Locations

The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 410-614-3853
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287 map

Johns Hopkins Outpatient Center

Appointment Phone: 410-614-3853
601 N. Caroline St.
Baltimore, MD 21287 map

Background

As Professor of Neurology, Oncology and Neuroscience and Co-Director of the Brain Cancer Disease Group at the Johns Hopkins Kimmel Cancer Center, Dr. John Laterra focuses on the diagnosis and treatment of patients with primary brain tumors and neurological complications of systemic cancer.

Dr. Laterra is internationally recognized for his clinical expertise and research on mechanisms of brain tumor malignancy, tumor vascular biology and the identification of new therapeutic targets in gliomas. Dr. Laterra's research is funded by the National Institutes of Health and numerous private foundations.

...read more

Titles

  • Co-Director, Brain Cancer Disease Group, Sidney Kimmel Comprehensive Cancer Center
  • Director, Division of Neuro-Oncology
  • Professor of Neurology
  • Professor of Neuroscience
  • Professor of Oncology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD; Case Western Reserve University School of Medicine (1984)

Residencies

  • Neurology; University of Michigan Health System (1988)

Board Certifications

  • American Board of Psychiatry and Neurology (Neurology-General) (1990)

Research & Publications

Selected Publications

View all on PubMed

Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, Burger P and Laterra J: Reversion of human glioblastoma malignancy by U1snRNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met gene expression.  J Natl Cancer Inst, 91:1548-1556, 1999. PMID: 10491431.

Kim KJ, Wang L, Su, YC, Gillespie GY, Salhotra A, Lal B and Laterra J.  Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res, 12(4):1292-1298, 2006. PMID: 16489086

Zhou J, Tryggestad E, Wen Z, Lal B, Zhou T, Grossman R, Yan K, Wang S, Fu D-X, Blakeley J, Ford E, Tyler B, Laterra J, and van Zijl PCM:  Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nature Med.2011 Jan; 17(1): 130-4.  Epub Dec 19 2010.  PMID:  21170048, PMCID:  PMC3058561.

Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, Xia S, Trageser D, Guerrero-Cázares H, Eberhart CG, Quiñones-Hinojosa A, Scheffler B, Laterra J: c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A. 108:9951-6, 2011. PMID: 21628563; PMCID:  PMC3116406.

Lopez-Bertoni H, Lal B, Michelson H, Guerrero-Cázares H, Quiñones-Hinojosa A, Li Y, Laterra J. Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells. Oncogene, 2016 Feb 22. doi: 10.1038/onc.2016.22. [Epub ahead of print].

Activities & Honors

Honors

  • Alpha Omega Alpha

Memberships

  • Journal of Neuro-Oncology

    Associate Editor

  • Scientific Advisory Board of the American Brain Tumor Association
  • The Society of Neuro-Oncology
    Charter Member

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • 4.9 Provider Explained Things Clearly
  • 4.9 Provider Listened Carefully
  • 4.9 Provider Knew Medical History
  • 4.9 Provider Showed Respect
  • 4.9 Provider Spent Enough Time
  • 4.9 Overall Rating by Patient

Comments

4.9 out of 5 (52 Ratings, 18 Comments)
Learn about Our Survey
    Is this you? Edit Profile
    back to top button